San Francisco – Sept. 12, 2007 - Synarc Inc., the world's leading provider of medical image analysis, biochemical marker, and clinical research center services to the pharmaceutical and biotechnology industries, announced that seven of its top scientists will be presenting at the American Society for Bone and Mineral Research (ASBMR) Annual Meeting September 16th-19th in Honolulu, Hawaii.
The scientists will be presenting new ideas and concepts on optimizing clinical trials of patients with bone disease. The Synarc presenters are: Claus Christiansen, MD, Klaus Engelke, PhD, Thomas Fuerst, PhD, Patrick Garnero, Phd, DSc, Harry Genant, MD, Paola Pettersen, MD and Luis Russo, MD
Dr. Christiansen is a co-founder of Synarc and founder of the Synarc Clinical Research Centers, previously the Center for Clinical and Basic Research. Dr. Engelke is a medical physicist with more than 15 years of experience in the application of advanced imaging techniques in osteoporosis and other diseases.
Dr. Fuerst is a medical physicist with more than 13 years of experience in bone densitometry and vertebral fracture methods for research and clinical trials. Dr. Garnero's research focuses on the development of new biochemical markers of bone, cartilage and synovium turnover. He is general manager and vice president of the Synarc Biochemical Marker Division.
Dr. Genant is a co-founder of Synarc and Professor Emeritus of Radiology, Orthopedic Surgery, Medicine and Epidemiology at the University of California San Francisco. Dr Genant is a co-founder and member of the board of directors of Synarc. Dr. Pettersen has been a radiologist at CCBR-Synarc in Denmark since 2004. During this period she has been publishing articles related to osteoporosis, osteoarthritis and mammography. Dr. Russo is an endocrinologist and director of the CCBR Brazil Clinical Research Center since 2003.
The ASBMR conference is designed for attendees to present new developments in education, research and clinical practice related to bone and mineral metabolism. The program objectives include updating attendees on the recent advances in osteoporosis and other diseases of bone and mineral metabolism, steroid hormones and receptors, calciotropic and phosphotropic hormones, cancer and bone, bone acquisition and pediatric bone disease, cartilage and connective tissue matrix, bone biomechanics, and growth factors.
Synarc is regarded as a global leader in osteoporosis studies. It currently has 37 studies being conducted world-wide. Synarc was formed in 1998 and since then has contributed to the approval of more leading compounds, across a broad spectrum of therapeutic areas, than any other central imaging provider.
About Synarc
Synarc’s medical image analysis, biochemical marker and clinical research center services enable life-science industry clients to execute clinical trials accurately while decreasing the time, uncertainty, and cost of product development. Synarc has partnered with industry leaders to bring numerous leading compounds to market across a broad spectrum of therapeutic areas. Our services integrate critical aspects of clinical-trial design and execution, from protocol design and subject recruitment to regulatory liaison on behalf of our clients. Our expert radiologists and scientists are innovators in all aspects of medical image analysis and biochemical markers in drug development, and have pioneered many methods used in today’s clinical trials. Synarc has seventeen offices around the world. Synarc's medical image analysis, biochemical marker and clinical research center services are currently used in more than 200 clinical trials around the world.
